Skin allergy problems such as atopic dermatitis, contact dermatitis and eczema are on the rise every year. Verperle® developed by ImDerma Laboratories has the effect of inhibiting allergy proved through experiments to be capable of suppressing the secretion of β-hexosaminidase, and granted patents in Taiwan, China and Japan. Furthermore, the latest patent application (Patent No. US 10561692 B2) was approved in February this year.